• Alexion Pharmaceuticals Inc., of Cheshire, Conn., reported total revenue of $76.5 million for the third quarter, all of which came from sales of paroxysmal nocturnal hemoglobinuria drug Soliris (eculizumab), which were up from the $21.8 million in revenues for the same quarter in 2007. The company's non-GAAP net income totaled $25.7 million, or 29 cents per share. Consensus estimates had projected earnings per share of 4 cents and revenue of $67 million. As of Sept. 30, Alexion had cash, equivalents, restricted cash and marketable securities of $126.4 million. Its shares (NASDAQ:ALXN) closed at $37.33 Friday, down $2.27.